Survival, PROs Favor Cemiplimab Plus Chemotherapy vs Chemotherapy Alone in Advanced NSCLC
For patients with advanced non–small cell lung cancer (NSCLC), regardless of PD-L1 status, cemiplimab plus chemotherapy had favorable survival benefits and patient-reported outcomes over chemotherapy alone.
Neoadjuvant Cemiplimab in CSCC Can Reduce Treatment Burden in Adjuvant Setting, Says Dr Neil D. Gross
Neoadjuvant cemiplimab followed by surgery resulted in favorable survival outcomes for patients with resectable stage II to IV cutaneous squamous cell carcinoma (CSCC), addressing an area of unmet need, explained Neil D. Gross, MD, FACS, of MD Anderson.
Amivantamab Plus Lazertinib Improved PFS for EGFR-Mutated Advanced NSCLC
MARIPOSA demonstrated the combination reduced risk of progression or death by 30% compared with osimertinib. MARIPOSA-2 found amivantamab plus chemotherapy and amivantamab plus chemotherapy and lazertinib also improved progression-free survival (PFS) over chemotherapy after progression on osimertinib.
Dr Helen Shih on Low-Grade Gliomas: Wait or Treat?
Helen Shih, MD, MS, MPH, FASTRO, Massachusetts General Hospital, weighs the risks and benefits of treating or postponing treatment of low-grade gliomas.
Dr Tina Cascone Details Impact of Nivolumab Chemo-Immunotherapy on NSCLC
Tina Cascone, MD, PhD, of the University of Texas MD Anderson Cancer Center, discusses the impact of the CheckMate 77T study on the treatment approach for non–small cell lung cancer (NSCLC).
TROPION-Breast01, TROPION-Lung01 Demonstrate PFS Benefit of Datopotamab Deruxtecan in Metastatic Breast Cancer, NSCLC
Datopotamab deruxtecan not only demonstrated a statistically significant improvement over chemotherapy for breast cancer and docetaxel for non–small cell lung cancer (NSCLC), but the intervention therapy had less toxicity.
Dr Thomas Powles Discusses Impact of EV+P Therapy on Urothelial Carcinoma Treatment
Thomas Powles, MD, MBBS, MRCP, from Barts Cancer Centre, shares insights from the EV-302/KEYNOTE-A39 trial and its implications for the future of enfortumab vedotin and pembrolizumab (EV+P) combination therapy for urothelial carcinoma.
First in Decades: Enfortumab Vedotin + Pembrolizumab Beats Chemo in First-Line Metastatic Urothelial Cancer
Enfortumab vedotin plus pembrolizumab not only beat chemotherapy in the first-line setting for locally advanced metastatic urothelial cancer for the first time in decades, but it nearly doubled progression-free survival and overall survival vs chemotherapy.
Trastuzumab Deruxtecan Demonstrates Efficacy Reducing Brain Metastases in HER2m NSCLC
Regardless of presence of brain metastases, patients with HER2-mutant (HER2m) non–small cell lung cancer (NSCLC) showed systemic responses to trastuzumab deruxtecan. In addition, the therapy showed intracranial efficacy to reduce the size of brain metastases.
Adding Adjuvant Nivolumab Builds on Standard of Care for Resectable NSCLC
The results of CheckMate 77T showcase the improved event-free survival for patients with resectable non–small cell lung cancer who receive nivolumab in both the neoadjuvant and adjuvant setting and may have practice-changing implications.
Overcoming the Efficacy-Effectiveness Gap in Cancer Therapy Research
With stringent criteria, randomized controlled trials are the cornerstone of cancer intervention research, but the result is they do not represent the majority of patients, which leads to a gap between the efficacy seen in trials and the effectiveness in the real-world setting.
Dr Kevin Kalinsky Shares Real-World Data on Effects of Sacituzumab Govitecan-hziy in TNBC
Kevin Kalinsky, MD, MS, of Glenn Family Breast Center, gives insight into the real-world data supporting the use of sacituzumab govitecan-hziy in the treatment of triple-negative breast cancer (TNBC).
Dr Max Parmar Details the Usefulness of MAMS Trial Designs
Max Parmar, professor of medical statistics and epidemiology at University College London, unpacks what clinicians and patients can gain from the application of multiarm multistage (MAMS) trials.
Frontline Pembrolizumab Plus Trastuzumab/Chemotherapy Improves PFS in HER2+ Gastric/GEJ Cancer
Adding pembrolizumab to combination of trastuzumab and chemotherapy improved progression-free survival vs placebo plus trastuzumab and chemotherapy in the first-line treatment of patients with metastatic HER2-positive gastric or gastroesophageal junction (GEJ) cancer.
Adagrasib Added to Pembrolizumab Safely, Effectively Treats Advanced NSCLC in Phase 2 KRYSTAL-7 Trial
The phase 2 KRYSTAL-7 trial evaluated adagrasib plus pembrolizumab in patients with KRAS-mutated non–small cell lung cancer (NSCLC) with high PD-L1 expression. The results demonstrated “encouraging preliminary activity.”
Addition of Adjuvant Abemaciclib Reduces Recurrence at 5 Years in HR+, HER2– High-Risk Early Breast Cancer
Results of the monarchE study showed patients with hormone receptor–positive (HR+), HER2-negative (HER2–) high-risk, early breast cancer had greater benefit after 5 years when receiving adjuvant abemaciclib plus endocrine therapy vs endocrine therapy alone.
Dr Pawel Sobczuk Previews Timely Themes of ESMO Congress 2023
Pawel Sobczuk, MD, PhD, of the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland, previews the upcoming ESMO Congress 2023 in Madrid, Spain.
ESMO to Highlight Immunotherapy Advances, Cancer Detection and Prevention, and the Needs of Caregivers
During ESMO Congress 2023, sessions will focus on hot topics in therapeutic areas, such as the use of immunotherapies in both the neoadjuvant and adjuvant settings, as well as nontherapeutic topics, such as the needs of caregivers and advances in technology.
2 Clarke Drive Cranbury, NJ 08512